TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 326593
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate and bendrofluazide (10 mg timolol and 2-5 mg bendrofluazide, increased as needed)
Study: 29497287
Drug: NEM 500
Normalized name: imipenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEM 500 mg
Study: 24884770
Drug: Patch repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch repair
Study: 18494967
Drug: Ozone followed
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone followed by P (8% carbamide peroxide solution)
Study: 18494967
Drug: Ozone concurrently
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone concurrently with P (8% carbamide peroxide solution)
Study: 18494967
Drug: P alone
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P alone (8% carbamide peroxide solution)
Study: 16435615
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of 0.75% ropivacaine + 25 microg of fentanyl
Study: 16435615
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of 1% ropivacaine + 25 microg of fentanyl
Study: 10099655
Drug: Adjuvant low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with MOPP/ABVD
Study: 10099655
Drug: Adjuvant low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with ABVD
Study: 10099655
Drug: Adjuvant low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with MOPP/ABVD or ABVD
Study: 2015545
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) plus doxorubicin as adjuvant chemotherapy
Study: 6779618
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg buccally
Study: 18839053
Drug: Metformin (1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,700 mg/day)
Study: 29519921
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prednisone for 7 days
Study: 26346638
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg/day
Study: 26346638
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 and 70 mg/day
Study: 17627903
Drug: Intrastricture steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrastricture steroid injection (triamcinolone, 40 mg total dose)
Study: 12389594
Drug: Transdermal estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogens (50 microg 17 beta‐Estradiol/24 hr)
Study: 12389594
Drug: Transdermal estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogens with progestagens (10 mg daily for last 2 weeks)
Study: 7936382
Drug: Transdermal estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogens
Study: 9649908
Drug: Insulin/C-peptide ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/C-peptide ratio
Study: 9649908
Drug: Insulin/C-peptide ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/C-peptide ratio (excluding muscle morphological variables)
Study: 8077174
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (sustained-release form, once a day at night, optimum dosage with plasma level of 0.5-0.79 mmol/L 12 hours after the nightly dose)
Study: 8077174
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (lower dosage after 1982)
Study: 2511685
Drug: Buccal NTG
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal NTG (1-3 mg t.i.d., five hourly with an eight-h washout period)
Study: 17928803
Drug: 8% (w/w)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% (w/w) solution of galactose (Gal)
Study: 17928803
Drug: 8% solution
Normalized name: Topicale 18% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% solution of 50% galactose/50% glucose (Gluc/Gal)
Study: 17928803
Drug: 8% solution
Normalized name: Topicale 18% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% solution of 80% glucose/20% fructose (Gluc/Fru)
Study: 8512659
Drug: Ro 42-5892
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42-5892 (600 mg)
Study: 3805544
Drug: Histamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.1 mg per nostril)
Study: 3805544
Drug: Histamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.5 mg per nostril)
Study: 3805544
Drug: Histamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (5 mg per nostril)
Study: 3805544
Drug: Histamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (10 mg per nostril)
Study: 31053954
Drug: Tolvaptan (weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (weight-adjusted doses, titrated to maintenance dose)
Study: 21261107
Drug: Perindopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (5 mg once daily, n = 20)
Study: 21261107
Drug: Rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1 mg once daily, n = 18)
Study: 21261107
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg once daily, n = 16)
Study: 17919555
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray 110 microg QD for 2 weeks
Study: 17919555
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray QD for 2 weeks
Study: 16246948
Drug: cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol 100 mg BID for 6 months
Study: 11243072
Drug: Purified Verocell
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Verocell Rabies Vaccine (PVRV)
Study: 8888092
Drug: Gentamicin-clindamycin (G-C)
Normalized name: (3'-5')d(c-a-c-g-c-a-c-g-c-g-c-a-t-c-c-c-c-g-c-c-c-g-t-g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-clindamycin (G-C)
Study: 1891675
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin A acid at 0.025% for 6 months followed by 0.05%
Study: 6130243
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (UCT)
Study: 3720528
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZ) 80 mg every third day (3 subjects) or every sixth day (3 subjects) for a total of 3-6 dosing occasions
Study: 3720528
Drug: Triazolam (TZ)
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam (TZ) 2.0 or 3.0 mg every second day (4 subjects) or every third day (2 subjects) for a total of 3-5 dosing occasions
Study: 30382270
Drug: Strawberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry supplementation (50 g day-1 for 12 weeks)
Study: 30382270
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 g day-1, matched for calories and fiber)
Study: 25684620
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL Evicel® (fibrin haemostatic sealant)
Study: 25684620
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of treatment with Evicel®
Study: 20578381
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (therapeutic principle of dredging meridians and collaterals, tonifying qi and eliminating blood stasis, supplementing liver and kidney, nourishing blood and tendon; points included Hegu (LI 4), Taichong (LR 3), Zusanli (ST 36), Qihai (CV 6), Quchi (LI 11))
Study: 20578381
Drug: Cobamamide (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobamamide (intramuscular injection)
Study: 2510510
Drug: Triple-drug immunosuppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug immunosuppressant therapy (cyclosporine, azathioprine, prednisone)
Study: 2510510
Drug: OKT3 prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 prophylaxis with 2 g intravenous methylprednisolone
Study: 776312
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (control group)
Study: 27594602
Drug: Psychoanalytic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic Therapy (PT)
Study: 22390832
Drug: One-hour in
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-hour in vivo exposure treatment
Study: 14520165
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg once daily
Study: 14520165
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg split dose
Study: 14520165
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg once daily
Study: 14520165
Drug: Modafinil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (all doses)
Study: 30975019
Drug: Cream denture
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream denture adhesive
Study: 27591988
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy
Study: 27591988
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical and NB-UVB therapy
Study: 29915975
Drug: NB-UVB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB-UVB therapy
Study: 25386609
Drug: Cynatine HNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cynatine HNS (500 mg keratin plus vitamins and minerals)
Study: 22788983
Drug: Life-review therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-review therapy with computer supplements (6 weeks)
Study: 17607121
Drug: Paclitaxel (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (110 mg/m2 on day 1), topotecan (1.5 mg/m2 on days 2-4), etoposide (160 mg/m2 on days 5-7 every 21 days) followed by chest irradiation to 70 Gy and carboplatin (AUC 5 on day 1) and etoposide (100 mg/m2 on days 1-3 every 21 days) without filgrastim for three cycles.
Study: 12270981
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg twice daily, n=11)
Study: 12270981
Drug: L-arginine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (100 mg/kg/30 min)
Study: 12270981
Drug: L-arginine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (500 mg/kg/30 min)
Study: 10097934
Drug: nisoldipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine (20-40 mg/day)
Study: 10097934
Drug: lisinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (10-20 mg/day)
Study: 8947977
Drug: Caffeine with
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine with multiple GFJ doses
Study: 31615021
Drug: Higher preconception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher preconception vegetable intake (per 10 g/day)
Study: 31615021
Drug: Higher preconception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher preconception fruit intake (per 10 g/day)
Study: 28403943
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (250,000 IU vitamin D3 bolus)
Study: 17560680
Drug: Terlipressin (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1-2 mg/4h) and albumin
Study: 9474615
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of oral acyclovir twice daily (1600 mg/day) for 3 to 7 days before sun exposure
Study: 3565338
Drug: Psyllium (7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (7.2 g/day)
Study: 3565338
Drug: Psyllium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium plus senna (6.5 + 1.5 g/day)
Study: 3565338
Drug: Both laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both laxatives
Study: 30477852
Drug: 5-week daily
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-week daily use of facial massage roller on the right cheek
Study: 24700490
Drug: Tafenoquine 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 1200 mg
Study: 24700490
Drug: Tafenoquine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 600 mg
Study: 17884359
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (high-dose)
Study: 17884359
Drug: Moderate statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate statin therapy (standard-dose)
Study: 8950071
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, given orally)
Study: 1742248
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg (Indocid)
Study: 1742248
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid 100 mg (Surgam)
Study: 1742248
Drug: Sodium acetylsalicylate
Normalized name: acetylsalicylate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium acetylsalicylate 1 g (Catalgine)
Study: 7081727
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine sulfate 10 mg
Study: 7081727
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural morphine 10 mg
Study: 28316174
Drug: ivabradine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (starting dose 5 mg bid, uptitrated to 7.5 mg bid)
Study: 24379072
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (Inhalation anesthesia with desflurane)
Study: 20598710
Drug: rEEG-guided pharmacotherapy
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rEEG-guided pharmacotherapy
Study: 17511752
Drug: Daily estimation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily estimation assessment procedures
Study: 14747225
Drug: Caiapo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caiapo (4 g once daily for 12 weeks)
Study: 9596235
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) loading infusion of 16 mmol followed by 65 mmol over 24 hours
Study: 9596235
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) loading infusion of 12 mmol followed by 65 mmol over 24 hours
Study: 9596235
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) loading infusion of 8 mmol followed by 65 mmol over 24 hours
Study: 2649156
Drug: State-Adjusted Treatment
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-Adjusted Treatment (SAT)
Study: 31013550
Drug: Δ9-tetrahydrocannabinol (THC)
Normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Δ9-tetrahydrocannabinol (THC) (8 mg)
Study: 31013550
Drug: THC +
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC + cannabidiol (THC + CBD) (8 + 16 mg)
Study: 31013550
Drug: CBD (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (16 mg)
Study: 21294997
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg loxapine
Study: 989370
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg loxapine
Study: 18246742
Drug: Ceftriaxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone treatment
Study: 11565669
Drug: 20-g albumin
Normalized name: ALBUMIN HUMAN 0.20 g in 1 mL INTRAVENOUS SOLUTION [FLEXBUMIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-g albumin
Study: 11565669
Drug: 2-g albumin
Normalized name: albumin human, USP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g albumin
Study: 7922833
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate 0.04 mg/kg followed by propranolol 0.2 mg/kg
Study: 3074299
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily (Group A)
Study: 3074299
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg once daily (Group B)
Study: 21722501
Drug: Hylan G-F20
Normalized name: HYLAN G-F20 16MG/2ML INJ,SYRINGE,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F20 (Synvisc)
Study: 19451093
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg b.i.d. for 4 weeks
Study: 16939509
Drug: Combined once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined once weekly high-velocity varied-resistance and once weekly gymnasium-based functional training (CB)
Study: 16335645
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PGE2 vaginal tablets (n = 75)
Study: 16335645
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL intracervical Foley catheter (n = 72)
Study: 11046104
Drug: xemilofiban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: xemilofiban (10 or 20 mg three times daily)
Study: 9505816
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin at a concentration of 5 IU/ml added to infusion fluid (n = 55)
Study: 9505816
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (control group, n = 56)
Study: 1447436
Drug: Standard electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard electronic oral (PO) thermometry
Study: 1447436
Drug: Rectal (R)
Normalized name: Rectal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal (R) thermometry
Study: 3903906
Drug: Pivampicillin, 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin, 700 mg twice daily for seven days
Study: 3903906
Drug: Metronidazole, 500
Normalized name: MetroNIDAZOLE, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole, 500 mg twice daily for seven days
Study: 29336426
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral methotrexate only (Group I)
Study: 29336426
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral methotrexate plus soak PUVAsol therapy twice weekly for three months (Group II)
Study: 20629598
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg LD/10 mg MD)
Study: 20629598
Drug: Prasugrel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (30 mg LD/7.5 mg MD)
Study: 20629598
Drug: Prasugrel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (30 mg LD/5 mg MD)
Study: 17414229
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg LD/75 mg MD)
Study: 20629598
Drug: Prasugrel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (all dosing regimens)
Study: 17959953
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 5 mg
Study: 15865226
Drug: Lamivudine therapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine therapy for 1 year (group 1a, n=19)
Study: 15865226
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment (group 1a)
Study: 12464959
Drug: Peanut protein
Normalized name: peanut protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut protein (various doses)
Study: 26448178
Drug: Nintedanib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (200 mg twice daily)
Study: 28380494
Drug: Accelerated up-dosing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals)
Study: 28380494
Drug: Conventional up-dosing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals)
Study: 25600249
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 25)
Study: 21888993
Drug: Dead Space
Normalized name: UltiCare 3mL 22G 1-1/2 inch Low Dead Space Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead Space Loading (DSL) 500 ml
Study: 3089467
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml iohexol
Study: 3089467
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml iohexol
Study: 29713851
Drug: Yiqi Fumai
Normalized name: Aspergillus fumigatus allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Fumai lyophilized injection (5.2 g) with 250 ml 5% glucose/sodium injection for 7 days
Study: 29713851
Drug: Standardized western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized western medications (control group) for 7 days